Recent Updates — IRLA
Quince Therapeutics has changed its name to IRulya Therapeutics Inc. effective October 9, 2026, following the completion of its merger with Orphai Therapeutics in May 2026. Dirk Thye resigned as Chief Executive Officer and Chief Medical Officer, while Brendan Hannah stepped down as Chief Operating Officer. Brigette Roberts was appointed CEO, John Militello CFO, and Keith Fandrick COO. The Board also added four new directors: Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise. Common stock will trade under the symbol IRLA on the Nasdaq Capital Market starting October 12, 2026. IRulya Therapeutics is a clinical-stage biopharmaceutical company focused on developing LAM-001 for pulmonary diseases.
Quince Therapeutics stockholders approved a Certificate of Amendment increasing authorized common shares from 250,000,000 to 275,000,000, effective October 6, 2026. The vote also ratified the adoption of the 2026 Equity Incentive Plan with an initial reserve of approximately 2.2 million shares and the 2026 Employee Stock Purchase Plan with a 142,045-share reserve. Additionally, shareholders approved issuances related to Series C Preferred conversion and Orphai warrants under Nasdaq rules. Quince Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.
Quince Therapeutics announced that Directors June Bray, David Lamond, and Christopher Senner tendered conditional resignations effective after the Special Meeting of Stockholders on October 6, 2026. The resignations are contingent upon stockholder approval of three proposals: converting Series C Preferred Stock and exercising related warrants (potentially representing over 20% of outstanding shares), approving a private placement for conversion proceeds under Nasdaq Rule 5635(d), and increasing authorized common stock from 250 million to 275 million. Concurrently, the Board conditionally appointed Catherine Bonuccelli, Leone Patterson, James Valentine, and Drayton Wise as new directors effective upon approval of these proposals. The company operates in the biopharmaceutical industry.
Quince Therapeutics completed the sale of its Italian subsidiary, Quince SpA, along with specific intellectual property related to its AIDE technology for Ataxia-Telangiectasia and associated equipment, to Ayma Therapeutics for $450,000 in cash. Concurrently, President Charles Ryan departed effective September 8, 2026, receiving a lump-sum severance payment of approximately $1.01 million under his executive agreement. The company operates in the biotechnology industry.
Quince Therapeutics received a notice from Nasdaq on August 31, 2026, for failing to meet the $10 million minimum stockholders' equity requirement, citing a deficit of ($35.3 million) as of June 30, 2026. The company has until October 15, 2026, to submit a compliance plan and may receive an extension until February 27, 2027. Quince is evaluating alternatives to regain compliance and references a pending listing application that could result in a name change to IRulya Therapeutics Inc. and a transfer to the Nasdaq Capital Market under the symbol IRLA. The company operates in the biotechnology industry.